Increased expressions of GLUT1 and GLUT3 are also linked with worse clinical outcomes in patients with glioblastoma and colorectal carcinoma (Cosset et al., 2017, Dai et al., 2020). Here, SLC2A1 is linked to colorectal carcinoma.